Insmed Inc. | Mutual Funds
Mutual Funds that own Insmed Inc.
T Rowe Price Health Sciences Fund
3,626,413
4.71%
-139,565
0.56%
06/30/2018
T Rowe Price New Horizons Fund
3,109,711
4.04%
-153,955
0.25%
06/30/2018
Fidelity Select Health Care Portfolio
2,555,505
3.32%
0
0.67%
07/31/2018
Vanguard Small Cap Index Fund
1,928,301
2.5%
23,631
0.04%
07/31/2018
Vanguard Total Stock Market Index Fund
1,923,348
2.5%
1,840
0.01%
07/31/2018
Janus Global Life Sciences Fund
1,807,760
2.35%
38,093
0.88%
06/30/2018
T Rowe Price Small Cap Stock Fund
1,623,739
2.11%
85,300
0.31%
06/30/2018
SPDR S&P Biotech ETF
1,608,420
2.09%
4,137
0.55%
09/06/2018
iShares Russell 2000 ETF
1,602,897
2.08%
-855
0.07%
09/06/2018
Fidelity VIP - Growth Portfolio
1,312,783
1.7%
0
0.44%
07/31/2018
| Address |
10 Finderne Avenue
Bridgewater New Jersey 08807
United States
|
|
Employees
|
- |
| Website |
http://www.insmed.com |
| Updated |
07/08/2019 |
| Insmed, Inc. operates as a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. It focuses on the development and commercialization of ARIKAYCE or liposomal amikacin for inhalation (LAI), for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. The company was founded on November 29, 1999 and is headquartered in Bridgewater, NJ. |
